Market Spotlight: Mantle Cell Lymphoma
|出版日期||內容資訊||英文 47 Pages
|關注市場分析:被套細胞淋巴瘤 (MCL) Market Spotlight: Mantle Cell Lymphoma|
|出版日期: 2019年11月29日||內容資訊: 英文 47 Pages||
本報告提供全球被套細胞淋巴瘤 (MCL) 市場相關調查，疾病的背景、概要，治療方法，開發平台治療藥概要，臨床試驗狀況等資料彙整。
This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were approximately 14,030 incident cases of mantle cell lymphoma (MCL) worldwide, and forecasts that number to increase to 18,010 incident cases by
2026. It is estimated that the majority of diagnosed cases were male in
2017. The incidence of MCL is highest among older individuals aged 60+ years. Approved drugs in the MCL space focus on a wide variety of targets. The majority of these drugs are administered via the oral route, with the remainder being available in intravenous and subcutaneous formulations.
The majority of industry-sponsored drugs in active clinical development for MCL are in Phase II. Therapies in active clinical development for MCL focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
High-impact upcoming events for drugs in the MCL space comprise topline Phase II trial results for KTE-X19 and parsaclisib, topline Phase II/III trial results for TG-1303 and umbralisib, and topline Phase III trial results for Imbruvica and Venclexta.
The overall likelihood of approval of a Phase I hematologic asset is 9.6%, and the average probability a drug advances from Phase III is 58.5%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been five licensing and asset acquisition deals involving MCL drugs during 2014-19. The largest deal was the $391.5m strategic collaboration and licensing agreement between Innovent and Incyte in 2018 to develop and commercialize Incyte's pemigatinib, itacitinib, and parsaclisib for hematology and oncology indications in China.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for MCL have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.
The US has a substantial lead in the number of MCL clinical trials globally. France and Germany lead the major EU markets, while South Korea has the top spot in Asia.
Johnson & Johnson has the highest number of completed clinical trials for MCL, with 13 trials. Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for MCL, followed by Celgene and Takeda.
8 Disease definition
8 Patient segmentation
8 Risk factors
10 Targeted therapies
11 Radiation therapy
11 Proteasome inhibitors
11 Stem cell transplantation
26 Copiktra for MCL (July 25, 2019)
26 Copiktra for MCL (March 6, 2019)
27 Revlimid for MCL (February 27, 2019)
28 Zevalin for MCL (January 17, 2019)
29 Brukinsa for MCL (December 1, 2018)
31 Brukinsa for MCL (December 1, 2018)
35 Brukinsa Sprints To Accelerated Approval For MCL
35 Accord Gets EMA Support For Arsenic Trioxide
35 BeiGene Wins Breakthrough Status For Zanubrutinib With Assist From Chinese Data
37 Deals Shaping The Medical Industry, April 2019
41 Sponsors by status
42 Sponsors by phase
45 Prescription information